1.World Health Organization. WHO characterizes COVID-19 as a pandemic Geneva: World Health Organization 2020. updated 31 July 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen.
2.World Health Organization. Update on Omicron Geneva 2021. 2022, 29 January. https://www.who.int/news/item/28-11-2021-update-on-omicron.
3.Centers for Disease Control and Prevention. COVID Data Tracker Washington 2022. 2022. https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
4.World Health Organization. Enhancing response to Omicron SARS CoV-2 variant Geneva2022. https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states.
5.Wang L, Cheng G. Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa. J Med Virol. 2021.
6.Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H, et al. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA. 2022;327(4):341-9.
7.Wald A. Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection. JAMA. 2022;327(4):327-8.
8.Nordström P, Ballin M, Nordström A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Lancet Reg Health Eur. 2021;11:100249.
9.Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomized, controlled, phase 2 trial. The Lancet. 2021;398(10318):2258-76.
10.Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022.
11.Garcia-Beltran WF, St Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022:S0092-8674(21)01496-3.